Rayner: Ilube bellyband on Eye News visible through postal wrapper ruled promotion of a POM to the public (AUTH/3334/4/20)

📅 2020 | 🖉 Dr Anzal Qurbain
📊

Key facts

CaseAUTH/3334/4/20
ComplainantHealth professional
CompanyRayner Pharmaceuticals Ltd
ProductIlube (acetylcysteine eye drops)
IssueJournal bellyband advertisement visible through transparent postal wrapper (potential public exposure)
Applicable Code year2019
Complaint received21 April 2020
Case completed3 July 2020
AppealNo appeal
Breach clausesClause 2; Clause 9.1; Clause 9.8; Clause 26.1
SanctionsUndertaking received; Additional sanctions: Not stated

Download the full case report (PDF)


Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI
🎬 Expert Video Walkthrough
🎬
Video walkthrough — coming for members
Subscribe now and get expert video analysis for every case as we publish them.
Subscribe — from £299/yr
📋

What happened

  • A health professional received a posted copy of Eye News with a wraparound “bellyband” advertisement for Ilube (acetylcysteine eye drops).
  • The advertisement was visible through the unopened, transparent plastic postal packaging, meaning it could be seen by members of the public during distribution.
  • The complainant alleged this breached the prohibition on promoting prescription-only medicines (POMs) to the public.
  • Rayner said the ad was intended for health professionals, used professional language, and was placed via the publication’s media package; Rayner said it did not intend public visibility and only later learned the journal was mailed in transparent plastic.
⚖️

Outcome

  • The Panel ruled that the Ilube advertisement was visible to the public in the post and therefore breached the Code.
  • The Panel found Rayner had not maintained high standards, noting a lack of evidence that anyone questioned whether the bellyband would be visible during mailing.
  • The Panel was concerned about lack of care/attention to detail on a matter reflecting UK law.
  • No appeal.
🔒

Unlock the full case analysis

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value
£249/year
Annual — save £99
or
£29/mo
Monthly
Join Now — Instant Access

⭐ Business Intelligence Access

See the full compliance picture for every pharma company

291 Company Intelligence Reports — breach patterns, appeal history, industry ranking, PDF export.

Request Access →
⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week — free.

Subscribe Free
🎓 AQP Training